Aligos Therapeutics
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of \[14C\]ALG-000184 and a Single Intravenous Dose of \[13C7,15N1\]ALG-001075 (Part C)
Inclusion Criteria: Key Inclusion Criteria 1. Parts A and B only: Male or female between 18 and 60 years of age 2. Part C only: Males between 18 and 55 years of age. 3. Body mass index between 18.0 kg/m2 and 32.0 kg/m2 4. In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments. 5. Part C only: History of a minimum of 1 bowel movement per day. Exclusion Criteria: Key Exclusion Criteria: 1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hep…
Single or multiple doses of ALG-000184
Single or multiple doses of Placebo
Single oral dose of \[14C\]ALG-000184
Single micodose of \[13C7,15N1\]ALG-001075 with combination of \[14C\]ALG-000184
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.